Evidence map›Paper›PMID 38584899›Full record

ArticleEuropean journal of case reports in internal medicine2024

A Rare Case of an Elderly Male with Progression to Chronic Myeloid Leukaemia Secondary to Chronic Lymphocytic Leukaemia.

Sakditad Saowapa, Watsachon Pangkanon, Yaw Adu, Nattanicha Chaisrimaneepan, Diego Olavarria Bernal, Natchaya Polpichai, Pharit Siladech, Jasmine Sekhon

Abstract read
In one paragraph

Article in European journal of case reports in internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sakditad SaowapaDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Watsachon PangkanonDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Yaw AduSchool of Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Nattanicha ChaisrimaneepanDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Diego Olavarria BernalDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Natchaya PolpichaiDepartment of Internal Medicine, Louis A Weiss Memorial Hospital, Chicago, USA.
Pharit SiladechInternal Medicine Department, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Jasmine SekhonDepartment of Hematology and Oncology, Texas Tech University Health Sciences Center, Lubbock, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukaemia (CLL) is a lymphoproliferative disorder characterised by an accumulation of monoclonal B lymphocytes, with an increased risk of secondary cancers. The coexistence of CLL and chronic myeloid leukaemia (CML) is a rare phenomenon, with three main types being classified: CML preceding CLL, CLL preceding CML and simultaneous occurrence. The coexistence of these chronic leukaemias poses a complex clinical challenge, with the underlying mechanisms of their association remaining enigmatic. Here, we present a report of an elderly male with a long history of CLL, who was subsequently diagnosed with secondary CML. LEARNING POINTS: The development of chronic myeloid leukaemia (CML) subsequent to chronic lymphocytic leukaemia (CLL) is an uncommon occurrence, challenging conventional expectations of disease evolution in chronic leukaemia.Extensive and appropriate testing is necessary to promptly identify secondary CML in CLL patients.Targeted therapy with dasatinib, a tyrosine kinase inhibitor, may demonstrate efficacy in reducing leukocytosis and

Indexed as

chronic lymphocytic leukaemiachronic myeloid leukaemiaCoexisting CLL/CMLdasatinib

Identifiers

PMID38584899
PMCPMC10997395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.